linjc16/ctgov huggingface dataset:
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi

Study Overview
=================
Brief Summary
-----------------
A novel infrared imaging tool to aid in the clinical detection of atypical pigmented lesions and melanoma is developed. Goals include evaluation of the utility of high-resolution infrared scanning of cutaneous lesions in the diagnosis of pigmented lesions and the identification of high-risk lesions and melanomas.

Detailed Description
-----------------
This study uses a specific skin protocol to cool the skin and then measures the cutaneous thermal recovery to uniquely identify lesions that may be cancerous. Using computer models, the thermal signature is used to determine the size and shape of the lesions in question. In particular, this study seeks to add quantification analysis of high resolution thermal images of melanoma lesions to provide accurate early diagnostic capability with specific detail regarding size, shape and depth of the lesions. This information will be compared to biopsy results and surgical resection results.

Official Title
-----------------
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi

Conditions
-----------------
Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients seen in the high-risk pigmented lesion clinic, who posses a pigmented lesion with a clinical indication for biopsy Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to Detect of the melanoma lesions | Using activated cooling methods we are measuring skin surface temperature recovery of specific lesions and comparing them to biopsy results of the lesions in question. | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of thermal signatures of benign cutaneous lesions |  | up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thermography
Registry of Laypeople's CPR Performance

Study Overview
=================
Brief Summary
-----------------
The aim of the registry is to collect laypeople's performance after a BLS/AED course carried out with the use of feedback devices.

Detailed Description
-----------------
The registry collect all the laypeople's performance of 1-minute of chest-compression only CPR registered at the end of a CPR/AED course in which feedback devices were used for at least 1 minute. All centers which carry out BLS/AED course for laypeople using CPR feedback devices can join to the registry. All the centers have to declare the duration of the course, the guidelines followed, the participants' anthropometric variables and the feedback device they used for the course and for the test. The centers must send the performances of all the participants of a course.

Official Title
-----------------
International Registry of Laypeople's CPR Performance After Training With Feedback Devices

Conditions
-----------------
Quality of Cardio-pulmonary Resuscitation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Layperson Participating in a BLS/AED course carried out with feedback devices Exclusion Criteria: Healthcare personnel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of adequate depth compression | Percentage of compression performed between 50 and 60 mm for each participant | 1 minute | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean compression depth | Mean compression depth for each participant | 1 minute | 
| Percentage of adequate rate compression | Percentage of compression performed between 100 and 120 per minute for each participant | 1 minute | 
| Compression per minute | Number of compressions per minute | 1 minute | 
| Percentage of correctly released compression | Percentage of compressions performed with complete chest recoil | 1 minute | 
| Percentage of correct hand position | Percentage of compressions performed with hands in the correct position | 1 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardio-Pulmonary Resuscitation, Cardiac Arrest, Training
Swedish Study on STroke After TAVR

Study Overview
=================
Brief Summary
-----------------
This study aims at studying the frequency of late stroke after transcatheter aortic valve replacement/implantation

Detailed Description
-----------------
Since the start of transcatheter aortic valve implnatations/replacements (TAVR/TAVI) implantations in Sweden in 2008 all procedures have been added to a national database, which now contains 5000+ procedures. At the same time, all admissions to the hospital is also recorded with diagnosis in a separate database. We intend to make a nation-wide complete follow up of all TAVR/TAVI patients in swede that has received the diagnosis of stroke after the implantation. In addition data will also be collected from the national stroke database for detailed information of the cases

Official Title
-----------------
Swedish Study on STroke After TAVR. A Nationwide All-comers Study of the Risk of Stroke After Transcatheter Aortic Valve Replacemant

Conditions
-----------------
Aortic Valve Disease, Stroke

Intervention / Treatment
-----------------
* Device: TAVR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that has under TAVR/TAVI in Sweden between 2008 and 2018 Exclusion Criteria: Patients unable to follow up due to emigration or missing social security number Exclusion Criteria: Periprocedural stroke
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient suffering a late stroke after TAVR<br>All patients suffering a stroke after TAVR will be studied | Device: TAVR<br>* Patient recieving a TAVR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke | Stroke as defined by the national stroke database | 5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TAVR, Stroke
Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy

Study Overview
=================
Brief Summary
-----------------
Otherwise healthy infants (1-12 months of age at the diagnosis) with CMA were prospectively evaluated. Patients with cow's milk protein-induced anaphylaxis, eosinophilic disorders of the gastrointestinal tract, and food protein induced enterocolitic syndrome were excluded. A food challenge was performed 6 and 12 months after the diagnosis to assess clinical tolerance acquisition. Main demographic and clinical characteristics were collected for each patient.

Conditions
-----------------
Cow's Milk Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Otherwise healthy infants (1-12 months of age at the diagnosis) with cow's milk allergy were prospectively evaluated Exclusion Criteria: Patients with cow's milk protein-induced anaphylaxis, eosinophilic disorders of the gastrointestinal tract, and food protein induced enterocolitic syndrome were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| infants receiving extensively hydrolysed casein formula<br>infants receiving extensively hydrolysed casein formula as substitutive formula | |
| extensively hydrolysed casein formula with Lactobacillus GG<br>infants receiving extensively hydrolysed casein with LGG as substitutive formula | |
| infants receiving rice hydrolyzed formula<br>infants receiving rice hydrolyzed formula as substitutive formula | |
| infants receiving soy-based formula<br>infants receiving soy-based formula as substitutive formula | |
| infants receiving amino-acid based formula<br>infants receiving amino-acid based formula as substitutive formula | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the effect of different dietotherapeutic approaches on the time of tolerance acquisition in children with cow's milk allergy | . Otherwise healthy infants (1-12 months of age at the diagnosis) with CMA were prospectively evaluated. Patients with cow's milk protein-induced anaphylaxis, eosinophilic disorders of the gastrointestinal tract, and food protein induced enterocolitic syndrome were excluded. A food challenge was performed 6 and 12 months after the diagnosis to assess clinical tolerance acquisition. Main demographic and clinical characteristics were collected for each patient. | about 4 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cow's milk allergy, formulas, probiotics
Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls

Study Overview
=================
Brief Summary
-----------------
Nitrogen-oxide (NO) plays an important role for blood pressure regulation, renal hemodynamics, and the renal excretion of sodium. NO is synthesized from L-arginine in the vascular endothelium and have a very short half-life in plasma and is therefore very difficult to measure directly. L-mono-methyl-L-arginine (L-NMMA) is an analogue to L-arginine and a competitive inhibitor of NO, and therefore can be used to study the effect of NO on the circulation. In normal subjects, infusion of L-NMMA will cause an increase in blood pressure, decreased renal plasma-flow, decreased glomerular filtration rate, and a decreased excretion of sodium. Hypothesis: Patients with obstructive sleep apnea has a decreased activity in the NO-system. This is contributing to the hypertension often seen in these patients. Decreased activity in the NO-system can be revealed by diminished fall in renal hemodynamic and sodium excretion after infusion of L-NMMA.

Conditions
-----------------
Obstructive Sleep Apnea, Healthy

Intervention / Treatment
-----------------
* Drug: L-NMMA (N-mono.methyl-L-arginine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obstructive sleep apnea Exclusion Criteria: Drug or alcohol abuse Pregnancy Disease of the heart, lungs, liver, kidney or endocrine organs Cerebral infarction Diabetes Gastrointestinal disease

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: L-NMMA (N-mono.methyl-L-arginine)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Everolimus on CKD Progression in ADPKD Patients

Study Overview
=================
Brief Summary
-----------------
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.

Detailed Description
-----------------
Considering the inhibitor activity of Everolimus on mTOR, our hypothesis is to evaluate its possible utility on the progression of CKD in ADPKD patients by reducing the rate of increase of renal cysts.

Official Title
-----------------
Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients

Conditions
-----------------
Polycystic Kidney Diseases

Intervention / Treatment
-----------------
* Drug: Everolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects over 18 years of both genders Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD) GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq Previous follow up of two years, with a creatinine evaluation at least once a year GFR reduction of at least 2.5 ml/min/year (according to MDRD formula) Exclusion Criteria: Pregnancy, lactating, males and females without adequate contraception Leucopenia (< 3,000 leucocytes/mm3) or thrombocytopenia (< 100,000 platelets/mm3) Dyslipidemia (cholesterol or triglycerides > 260 mg/dl with treatment) Urinary tract infection Patients who cannot undergoing NMR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Everolimus<br>Everolimus + standard therapy for CKD | Drug: Everolimus<br>* 0.75 mg x 2 / day<br>* Other names: mTOR inhibitors;|
| No Intervention: Control<br>Standard therapy for CKD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of GFR (according to MDRD formula) during a two-year follow up |  | Two year-followup | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction of creatinine clearance and GFR (according to Cockcroft-Gault formula) during a two-year follow up |  | Two year-followup | 
| changes in kidney size and renal and liver cysts dimensions evaluated by NMR at basal and at the end of the study |  | Two year-followup | 
| safety profile of everolimus (leucopenia, thrombocytopenia, lipid profile and other adverse events |  | Two year-followup | 
| evaluation of phosphatemia, phosphaturia and urinary cytokines on primary end point |  | Two year-followup | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADPKD, CKD, Renal disease progression, Everolimus
A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside

Study Overview
=================
Brief Summary
-----------------
To provide a point-in-time measurement of the oral health of elderly inpatients across the trust (elderly defined here as over 70 years). This will provide information about the number of teeth, need for restorative and periodontal treatment, and extractions, the health of the oral mucosa, quality of any dentures and hygiene of the teeth and dentures.

Detailed Description
-----------------
Such information will allow identification of any problems with oral health in this hospital population, thereby allowing development of strategies and protocols for managing these problems. There have been a number of studies examining these variables in elderly residents in care homes and a few in long term hospital settings (over 1 year admission), but only one in the UK previously in acute hospitals. Therefore the published literature is sparse, and requires further data collection. The oral health of the elderly, but particularly the institutionalized, is increasingly recognised for its important relationships with general health, wellbeing and quality of life. This study will provide useful information to address these concerns.

Official Title
-----------------
A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside

Conditions
-----------------
Oral Health

Intervention / Treatment
-----------------
* Other: no intervention - cross-sectional observational only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 70 or over and admitted to geriatric ward within the study area, able to consent Exclusion Criteria: unable to consent, aged under 70

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants<br>Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study | Other: no intervention - cross-sectional observational only<br>* no intervention - cross-sectional observational only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of oral hygiene | using modified plaque index | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| age | age in years | 1 month | 
| gender | male or female | 1 month | 
| condition of oral mucosa | presence of absence of specific disease, e.g. candidosis, leukoplakia | 1 month | 
| number of broken and decayed teeth | a simple count of the number of decayed and broken teeth present | 1 month |
Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with major hepatectomy.

Detailed Description
-----------------
The investigators reported that preoperative immunonutrition improve the incidence of postoperative infectious complication in patients after hepatectomy, and modulation of Th1/Th2 differentiation may play important roles in this effect. Object of this study is to investigate the effects of preoperative immunonutrition on incidence of postoperative infectious complication, and Th1/Th2 balance after hepatectomy.

Official Title
-----------------
Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy

Conditions
-----------------
Bile Duct Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: Oral IMPACT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hepatectomy Exclusion Criteria: age younger than 18 years ongoing infection gastrointestinal obstruction respiratory dysfunction cardiac dysfunction hepatic dysfunction renal failure history of recent immunosuppressive or immunological disease preoperative evidence of widespread metastatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group A<br>preoperative immunonutrition | Dietary Supplement: Oral IMPACT<br>* oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA<br>* Other names: Oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan;|
| No Intervention: group B<br>ordinary diet | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative infectious complication |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma IL-6, CRP, Th1/Th2 balance |  | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
immunonutrition, hepatectomy, Th1, Th2
Acute Congestive Heart Failure Urgent Care Evaluation

Study Overview
=================
Brief Summary
-----------------
This prospective validation study evaluates the ability of a risk algorithm, which can simultaneously predict the risk of death at 7 days and 30 days for patients with acute heart failure presenting to the emergency department. The risk algorithms for prediction of 7-day (Emergency Heart failure Mortality Risk Grade [EHMRG]) and 30-day mortality (EHMRG30-ST) have been previously derived.

Official Title
-----------------
Acute Congestive Heart Failure Urgent Care Evaluation: Prospective Validation of the Emergency Heart Failure Mortality Risk Grade 7-day and 30-day Algorithms in the Emergency Department

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute heart failure diagnosed in the emergency department Exclusion Criteria: Palliative or do-not-resuscitate (DNR) directive Dialysis dependent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death within 7 days after emergency department presentation for heart failure | 7 days | 
| Mortality | Death within 30 days after emergency department presentation for heart failure | 30 days |